After August 17, 2026, Novus Biologicals products and services will no longer be available on this website; you will access all products and services on rndsystems.com. Create your R&D Systems online account today.
1344-SE), DU145 human prostate carcinoma cell line, and LNCaP human prostate cancer cell line. PVDF membrane was probed with 0.5 µg/mL of Goat Anti-Human Kallikrein 3/PSA Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1344) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for Kallikrein 3/PSA at approximately 28-30 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox" target="_blank">
HAF019). A specific band was detected for Kallikrein 3/PSA at approximately 31 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1." class="big_lightbox" target="_blank">
NL001) and counterstained with DAPI (blue). Specific staining was localized to cytoplasm of LNCaP cells. View our protocol for Fluorescent ICC Staining of Cells on Coverslips." class="big_lightbox" target="_blank">
1344-SE) was serially diluted and captured by Mouse Anti-Human Kallikrein 3/PSA Monoclonal Antibody (Catalog # MAB13442) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human Kallikrein 3/PSA Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1344) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" class="big_lightbox" target="_blank">
PSA is a chymotrypsin-like serine protease (kallikrein family) produced by the prostate epithelium, and abundant in seminal fluid. PSA can be detected in the sera of patients with prostatic carcinoma. It is predominantly complexed to a liverderived serine protease inhibitor, alpha-1-antichymotrypsin (ACT). A higher proportion of serum PSA is complexed to ACT in prostate cancer than in benign prostate hyperplasia.